A Great Divide: Sponsors Clash With FDA on Trial Data Excess
A new study, conducted collaboratively by the Tufts Center for the Study of Drug Development (Tufts CSDD), the FDA,...
Clinical Trial GCP Focus: Powerful QA Strategies Revealed
One of the most well-received presentations from Momentum Events’ December 2023 2nd GCP Inspection Readiness Conference was Tony Johnson,...
Revolutionary J-Brain Cargo® Tech in JCR Alexion Deal
JCR Pharmaceuticals Co., Ltd. has entered into a Research Collaboration, Option, and License Agreement with Alexion, AstraZeneca Rare Disease,...
FDA Unveils Groundbreaking Rare Disease Guidance Document
In a landmark move, the U.S. Food and Drug Administration (FDA) has released a detailed guidance document titled “Rare...
China’s Bold Takeda Choice: LIVTENCITY’s Unique Edge
Takeda has announced the approval of LIVTENCITY® (maribavir) by the National Medical Products Administration (NMPA) of China for treating...
AI in Action: Medidata Focuses on Data Entry, Diverse Trials
Dive into the forefront of clinical trial innovation with our interview featuring Anthony Costello from Medidata. We discuss groundbreaking...
Breaking New Ground: AstraZeneca, Roche, Acadia in GCP & AI
The 2nd GCP Inspection Readiness Conference, convened by Momentum Events, attracted a significant gathering of clinical experts in the...
uMotif Shaping New Patient-Centric Design in Clinical Trials
In today’s dialogue, we are privileged to converse with Bruce Hellman from uMotif, a company at the forefront of...
AstraZeneca & Daiichi Breakthrough Trial: New Breast Cancer Therapy Tested
Daiichi Sankyo and AstraZeneca have begun dosing the first patient in two global, randomized Phase 3 trials of their...
Gilead’s $848M Bet on Compugen’s Revolutionary Therapy
Gilead Sciences, Inc. has entered into an agreement with Israeli company Compugen Ltd., a clinical-stage cancer immunotherapy firm, to...